|
1
|
Menon MP, Pittaluga S and Jaffe ES: The
histological and biological spectrum of diffuse large B-cell
lymphoma in the World Health Organization classification. Cancer J.
18:411–420. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gustafson HL, Yao S, Goldman BH, Lee K,
Spier CM, LeBlanc ML, Rimsza LM, Cerhan JR, Habermann TM, Link BK,
et al: Genetic polymorphisms in oxidative stress-related genes are
associated with outcomes following treatment for aggressive B-cell
non-Hodgkin lymphoma. Am J Hematol. 89:639–645. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Peroja P, Pasanen AK, Haapasaari KM,
Jantunen E, Soini Y, Turpeenniemi-Hujanen T, Bloigu R, Lilja L,
Kuittinen O and Karihtala P: Oxidative stress and redox
state-regulating enzymes have prognostic relevance in diffuse large
B-cell lymphoma. Exp Hematol Oncol. 1:22012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Uruno A and Motohashi H: The Keap1-Nrf2
system as an in vivo sensor for electrophiles. Nitric Oxide.
25:153–160. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ahmed SM, Luo L, Namani A, Wang XJ and
Tang X: Nrf2 signaling pathway: Pivotal roles in inflammation.
Biochim Biophys Acta. 1863:585–597. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhang DD: The Nrf2-Keap1-ARE signaling
pathway: The regulation and dual function of Nrf2 in cancer.
Antioxid Redox Signal. 13:1623–1626. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yamazaki H, Tanji K, Wakabayashi K,
Matsuura S and Itoh K: Role of the Keap1/Nrf2 pathway in
neurodegenerative diseases. Pathol Int. 65:210–219. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Barančík M, Grešová L, Barteková M and
Dovinová I: Nrf2 as a key player of redox regulation in
cardiovascular diseases. Physiol Res. 65(Suppl 1): S1–S10.
2016.PubMed/NCBI
|
|
9
|
Sandford AJ, Malhotra D, Boezen HM,
Siedlinski M, Postma DS, Wong V, Akhabir L, He JQ, Connett JE,
Anthonisen NR, et al: NFE2L2 pathway polymorphisms and lung
function decline in chronic obstructive pulmonary disease. Physiol
Genomics. 44:754–763. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Swerdlow SH, Campo E, Pileri SA, Harris
NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz
AD and Jaffe ES: The 2016 revision of the World Health Organization
classification of lymphoid neoplasms. Blood. 127:2375–2390. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Taguchi K and Yamamoto M: The KEAP1-NRF2
system in cancer. Front Oncol. 7:852017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cheng ML, Lu YF, Chen H, Shen ZY and Liu
J: Liver expression of Nrf2-related genes in different liver
diseases. Hepatobiliary Pancreat Dis Int. 14:485–491. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Batliwala S, Xavier C, Liu Y, Wu H and
Pang IH: Involvement of Nrf2 in ocular diseases. Oxid Med Cell
Longev. 2017:17038102017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pasanen AK, Kuitunen H, Haapasaari KM,
Karihtala P, Kyllönen H, Soini Y, Turpeenniemi-Hujanen T and
Kuittinen O: Expression and prognostic evaluation of oxidative
stress markers in an immunohistochemical study of B-cell derived
lymphomas. Leuk Lymphoma. 53:624–631. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang J, Wang X, Wu W, Dang H and Wang B:
Expression of the Nrf2 and Keap1 proteins and their clinical
significance in osteosarcoma. Biochem Biophys Res Commun.
473:42–46. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Soini Y, Eskelinen M, Juvonen P, Kärjä V,
Haapasaari KM, Saarela A and Karihtala P: Nuclear Nrf2 expression
is related to a poor survival in pancreatic adenocarcinoma. Pathol
Res Pract. 210:35–39. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang J, Wang X, Vikash V, Ye Q, Wu D, Liu
Y and Dong W: ROS and ROS-mediated cellular signaling. Oxid Med
Cell Longev. 2016:43509652016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Itoh K, Wakabayashi N, Katoh Y, Ishii T,
Igarashi K, Engel JD and Yamamoto M: Keap1 represses nuclear
activation of antioxidant responsive elements by Nrf2 through
binding to the amino-terminal Neh2 domain. Genes Dev. 13:76–86.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Moi P, Chan K, Asunis I, Cao A and Kan YW:
Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic
leucine zipper transcriptional activator that binds to the tandem
NF-E2/AP1 repeat of the beta-globin locus control region. Proc Natl
Acad Sci USA. 91:9926–9930. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Villeneuve NF, Lau A and Zhang DD:
Regulation of the Nrf2-Keap1 antioxidant response by the ubiquitin
proteasome system: An insight into cullin-ring ubiquitin ligases.
Antioxid Redox Signal. 13:1699–1712. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang M, Zhang C, Zhang L, Yang Q, Zhou S,
Wen Q and Wang J: Nrf2 is a potential prognostic marker and
promotes proliferation and invasion in human hepatocellular
carcinoma. BMC Cancer. 15:5312015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kawasaki Y, Ishigami S, Arigami T,
Uenosono Y, Yanagita S, Uchikado Y, Kita Y, Nishizono Y, Okumura H,
Nakajo A, et al: Clinicopathological significance of nuclear factor
(erythroid-2)- related factor 2 (Nrf2) expression in gastric
cancer. BMC Cancer. 15:52015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Isohookana J, Haapasaari KM, Soini Y and
Karihtala P: Keap1 expression has independent prognostic value in
pancreatic adenocarcinomas. Diagn Pathol. 10:282015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Shibata T, Kokubu A, Saito S,
Narisawa-Saito M, Sasaki H, Aoyagi K, Yoshimatsu Y, Tachimori Y,
Kushima R, Kiyono T and Yamamoto M: NRF2 mutation confers malignant
potential and resistance to chemoradiation therapy in advanced
esophageal squamous cancer. Neoplasia. 13:864–873. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shibata T, Kokubu A, Gotoh M, Ojima H,
Ohta T, Yamamoto M and Hirohashi S: Genetic alteration of Keap1
confers constitutive Nrf2 activation and resistance to chemotherapy
in gallbladder cancer. Gastroenterology. 135:1358–1368, 1368. e1-4.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hayes JD and McMahon M: NRF2 and KEAP1
mutations: Permanent activation of an adaptive response in cancer.
Trends Biochem Sci. 34:176–188. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Singh A, Boldin-Adamsky S, Thimmulappa RK,
Rath SK, Ashush H, Coulter J, Blackford A, Goodman SN, Bunz F,
Watson WH, et al: RNAi-mediated silencing of nuclear factor
erythroid-2-related factor 2 gene expression in non-small cell lung
cancer inhibits tumor growth and increases efficacy of
chemotherapy. Cancer Res. 68:7975–7984. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Genrich G, Kruppa M, Lenk L, Helm O,
Broich A, Freitag-Wolf S, Rocken C, Sipos B, Schäfer H and Sebens
S: The anti-oxidative transcription factor Nuclear factor E2
related factor-2 (Nrf2) counteracts TGF-β1 mediated growth
inhibition of pancreatic ductal epithelial cells -Nrf2 as
determinant of pro-tumorigenic functions of TGF-β1. BMC Cancer.
16:1552016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Nioi P and Nguyen T: A mutation of Keap1
found in breast cancer impairs its ability to repress Nrf2
activity. Biochem Biophys Res Commun. 362:816–821. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Khatri R, Shah P, Guha R, Rassool FV,
Tomkinson AE, Brodie A and Jaiswal AK: Aromatase inhibitor-mediated
downregulation of INrf2 (Keap1) leads to increased Nrf2 and
resistance in breast cancer. Mol Cancer Ther. 14:1728–1737. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Stacy DR, Ely K, Massion PP, Yarbrough WG,
Hallahan DE, Sekhar KR and Freeman ML: Increased expression of
nuclear factor E2 p45-related factor 2 (NRF2) in head and neck
squamous cell carcinomas. Head Neck. 28:813–818. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Frohlich DA, McCabe MT, Arnold RS and Day
ML: The role of Nrf2 in increased reactive oxygen species and DNA
damage in prostate tumorigenesis. Oncogene. 27:4353–4362. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zembutsu H: Keap1-Nrf2 pathway and drug
resistance in epithelial ovarian cancer. Pharmacogenomics.
12:1516–1517. 2011.PubMed/NCBI
|
|
34
|
Shim GS, Manandhar S, Shin DH, Kim TH and
Kwak MK: Acquisition of doxorubicin resistance in ovarian carcinoma
cells accompanies activation of the NRF2 pathway. Free Radic Biol
Med. 47:1619–1631. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ma JQ, Tuersun H, Jiao SJ, Zheng JH, Xiao
JB and Hasim A: Functional role of NRF2 in cervical carcinogenesis.
PLoS One. 10:e01338762015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zha J, Chen F, Dong H, Shi P, Yao Y, Zhang
Y, Li R, Wang S, Li P, Wang W and Xu B: Disulfiram targeting
lymphoid malignant cell lines via ROS-JNK activation as well as
Nrf2 and NF-kB pathway inhibition. J Transl Med. 12:1632014.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Chen Z, Pittman EF, Romaguera J, Fayad L,
Wang M, Neelapu SS, McLaughlin P, Kwak L and McCarty N: Nuclear
translocation of B-cell-specific transcription factor, BACH2,
modulates ROS mediated cytotoxic responses in mantle cell lymphoma.
PLoS One. 8:e691262013. View Article : Google Scholar : PubMed/NCBI
|
